cho_logo_symbol_border

Study: MERS, SARS, and Ebola: The Role of Super-Spreaders in Infectious Disease

By GaryWong WenjunLiu YingxiaLiu BopingZhou Youhai Bi, George F.Gao  Published 14 October 2015

SCIENCE DIRECT

Super-spreading occurs when a single patient infects a disproportionate number of contacts. The 2015 MERS-CoV, 2003 SARS-CoV, and to a lesser extent 2014–15 Ebola virus outbreaks were driven by super-spreaders. We summarize documented super-spreading in these outbreaks, explore contributing factors, and suggest studies to better understand super-spreading.

A number of recent virus outbreaks have resulted in rapid virus spread, placing demands on the affected health infrastructures and sparking global concern. In September 2012, Middle East Respiratory Syndrome coronavirus (MERS-CoV) emerged as a novel virus that can result in severe respiratory disease with renal failure, with a case fatality rate of up to 38%. Primary infections typically occur in countries located in the Middle East, where dromedary camels have been identified as one of the species harboring the virus. However, travel has contributed to several cases in other countries. Notably, between May and July 2015, an outbreak of MERS-CoV centered in South Korea killed 36 people out of 186 confirmed cases (Promedmail.org, 2015), with thousands quarantined as health authorities attempted to control virus spread.

Severe Acute Respiratory Syndrome coronavirus (SARS-CoV), a close relative of MERS-CoV, was the etiological agent responsible for an outbreak centered around Guangdong Province in the southeast of China. The SARS-CoV outbreak killed 774 and infected 8,096 people between November 2002 and July 2003, for a case fatality rate of 9.6%, in which the virus was first traced to palm civets, and then bats. Over 80% of the total cases and deaths were from mainland China and Hong Kong.

More recently, a devastating Ebola virus (EBOV) outbreak has swept through Western Africa. EBOV is a filovirus that causes severe hemorrhagic fever in humans with up to a 90% case fatality rate if untreated. Outbreaks of EBOV are sporadic, unpredictable, and localized to sub-Saharan Africa. Prior to the 2014–15 outbreak, a total of 1,093 deaths out of 1,393 infections were documented dating back to 1976, when EBOV first emerged. The natural reservoir of EBOV is currently unknown, but fruit bats are suspected to be the animal species harboring the virus.

In addition to their significant impact, these outbreaks were all perpetuated by super-spreaders who disproportionately infect a high number of contacts and likely contribute to the speed and degree of the outbreak. As discussed in detail below, these outbreaks can be traced to one or more individuals who largely contributed to subsequent infections.

The SARS-CoV Outbreak

Retrospectively, several super-spreading events were also documented during the SARS-CoV outbreak in 2003. The index patient of the Hong Kong epidemic was treated at Prince of Wales Hospital and was associated with at least 125 secondary cases (Riley et al., 2003). Subsequent super-spreader events occurred at the Hotel Metropole (13 cases) and the Amoy Gardens housing complex (over 180 cases) in Hong Kong and aboard an Air China flight traveling from Hong Kong to Beijing (22 cases) (Braden et al., 2013). Notably, cases from Hotel Metropole were responsible for the spread of SARS-CoV to Canada, Vietnam, and Singapore through travel (Figure 1B), and the imported case to Canada resulted in 128 SARS-CoV cases at a Toronto hospital (Braden et al., 2013).

Have Super-Spreaders Played a Role in Other Outbreaks?

To a lesser extent, similar events were observed with the 2014-15 EBOV outbreak, centered in the Western African countries of Guinea, Sierra Leone, and Liberia. Epidemiological work has linked five infections with a 2-year-old toddler in the remote village of Meliandou, Guinea. One of the contacts, a midwife, infected at least three others, including a hospital worker at Guéckédou hospital. This worker then infected several family members in the Guéckédou Farako district, as well as 15 others at Macenta hospital (Baize et al., 2014). One of the subsequent cases, a doctor, was known to have infected several others who traveled to Kissidougou and Nzérékoré, further propagating virus transmission (Baize et al., 2014). The outbreak eventually spilled over to neighboring Liberia and Sierra Leone. In Sierra Leone, the funeral of a traditional healer that died from EBOV was shown to have directly infected 13 others (Gire et al., 2014) and was eventually linked to more than 300 cases (WHO, 2015b). The EBOV outbreak has killed 11,284 people, with 27,741 infected as of July 19 2015, en route to becoming the largest filovirus outbreak ever documented. In addition to EBOV, super-spreading has also been documented in outbreaks with other pathogens, including measles (Paunio et al., 1998) and Mycobacterium tuberculosis (Kline et al., 1995).

Why Is the Super-Spreader Phenomenon Important?

The initial stages of the outbreaks mentioned above involved at least one super-spreading event. The ability of the pathogen to infect subsequent super-spreaders who may export the disease through travel is likely the difference between an infection cluster and an outbreak or epidemic (Figure 1C). Differences in the initial response to MERS-CoV is why South Korea reported clusters of infections before bringing the virus under control and why China, Thailand, and the Philippines have not reported any additional cases despite imported MERS-CoV infections. It was why SARS-CoV was so devastating in mainland China and Hong Kong from 2002 to 2003. It was also why the 2014–15 EBOV outbreak spiraled out of control in Western Africa, with hundreds of new cases reported weekly, before a coordinated international effort (including contact tracing, isolation, diagnosis, and treatment of infected patients, as well as community education) brought the number down to a more manageable 20–30 weekly infections, with most of the cases diagnosed in Guinea and Sierra Leone. Early discovery, diagnosis, intervention, and quarantine of confirmed cases is crucial for preventing further disease transmission in humans, especially via super-spreaders. As evidenced by the decreased numbers of new cases in the MERS-CoV and EBOV outbreaks, current responses are effective, provided that the measures are implemented properly and followed strictly. Vigilance and patience will be necessary until the ongoing MERS-CoV and EBOV outbreaks are officially at an end.

Approaches or Guidelines that Can Proactively Identify Super-Spreaders

Currently, super-spreaders are only retrospectively categorized after epidemiological tracing. Given their high propensity to spread infection, super-spreaders should be able to shed higher levels of pathogen and/or for a longer period of time after infection. This would increase the probability that the pathogen contacts and subsequently infects a naive host.

To address whether there are factors or parameters that promote or indicate enhanced virus shedding in a laboratory setting, an animal species that closely recapitulates symptoms of the human disease is required, such that any findings can be translated to humans. Animals could be experimentally infected with different virus strains/variants at varying doses via different challenge routes, in which virus shedding from the oral, nasal, and rectal cavities should be correlated with different parameters, including viremia or virus titers in the organs. However, these studies are currently challenging for SARS-CoV as there is currently not an appropriate animal model that replicates the severe disease seen in humans; infected nonhuman primates exhibit variable, but at most mild to moderate, respiratory disease (McAuliffe et al., 2004) (Lawler et al., 2006). Nonetheless, these types of studies are feasible for MERS-CoV. A model of this infection was developed in the common marmoset that results in severe respiratory disease and partial lethality, in which live virus can be detected in nasal and throat swabs of infected animals (Falzarano et al., 2014). Thus, the studies proposed above can be investigated with MERS-CoV in this animal model.

For EBOV, the cynomolgus and rhesus macaque animal models are well characterized and have been used over the past 20+ years. EBOV shedding is known to occur from the oral, nasal, and/or rectal cavities of nonhuman primates during the advanced stages of disease, but factors that influence virus shedding from these animals have not yet been investigated. Interestingly, using a guinea pig model, it was shown that animals infected intranasally (i.n.) with guinea pig-adapted EBOV were more contagious to naive contact animals than those that were infected intraperitoneally (i.p.) with the same dose (Wong et al., 2015). I.n. infected animals shed virus from their nasal cavity earlier than their i.p. counterparts, and i.p. challenged animals died earlier (and thus were removed from contact with naive animals) compared to i.n. inoculated guinea pigs. It was therefore concluded that the route of infection in addition to the duration of contact time with an infectious host may be factors that influence the efficiency of virus transmission. It will take time to elucidate all possible host and viral factors that contribute to virus shedding, which remains an understudied topic to date. Therefore, it is not currently possible to predict with any level of confidence or statistical significance whether a person will become a super-spreader of a certain disease. Large-scale genome-wide association studies (GWAS) of super-spreaders might provide some clues about the genetic backgrounds of super-spreaders, but the feasibility and robustness of these analyses will depend on the number of super-spreaders in a given outbreak.

Leave A Comment

Your email address will not be published. Required fields are marked *

 

Our Journey to $1B+ Valuation

 

Disrupting Healthcare Testing / Diagnostics Early Detection of Cancer,
Chronic Conditions, Disease, Unlocking Anti-Aging Genomics & Promoting Longevity.

 

FUNDING GOAL $5,000,000

Funding Goal $5,000,000

20%

Skip to content